IRF4:NSCLC

Qian Zhao1, Butuo Li2, Yiyue Xu2

  • 1Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430064, China; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, Shandong, China.

PubMed
概括

高的干扰素调节因子4 (IRF4) 表达预测了接受免疫治疗的非小细胞肺癌 (NSCLC) 患者的更好的结果. 这一发现支持IRF4作为个性化NSCLC治疗策略的生物标志物.